

CLINICAL RESEARCH HIGHLIGHTS – DIABETES MANAGEMENT

In a clinical evaluation conducted over approximately **90 DAYS**,
the reported outcomes included:

CLINICAL PARAMETER	REPORTED OUTCOME
 HbA1c (Glycated Hemoglobin)	 2.5–3 PERCENTAGE POINTS reduction
 Fasting Blood Sugar (FBS)	 54% reduction
 Post-Prandial Blood Sugar (PPBS)	 50% reduction
 HOMA-IR (Insulin Resistance)	 Improvement in INSULIN-RESISTANCE parameters
 HOMA-B (β -cell Function)	 Improvement in β-CELL FUNCTIONAL parameters



These findings indicate **POTENTIAL SUPPORT** for
IMPROVED GLYCAEMIC CONTROL, INSULIN SENSITIVITY
and **β -CELL FUNCTIONAL PARAMETERS**
when the formulation is used within an appropriate diabetes-management program.



Reference-

1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10225382/>
2. <https://www.sciencerepository.org/review-data?doi=10.31487/j.JDMC.2022.01.02>
3. https://m.sciencerepository.org/pharmacological-potential-of-advance_RGM-2022-2-101
4. <https://www.sciencerepository.org/abstract?doi=10.31487/j.RGM.2022.01.03>